Background. It is not understood why only a subset of individuals infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy (CCC). Patients with CCC display high levels of circulating proinflammatory cytokines. Heart-infiltrating lymphocytes from patients with CCC also express proinflammatory cytokines (tumor necrosis factor-a and interferon-g) that are detectable in biopsy samples and surgical heart-tissue samples. BAT1, a putative anti-inflammatory gene, presents functional polymorphisms in its promoter region that influence its transcriptional level.
The BAT1 gene, also known as UAP56, is a member of the DEAD-box family of ATP-dependent RNA helicases [1] . BAT1 is situated in the central region of the major histocompatibilty complex (MHC) on the short arm of human chromosome 6 and is ∼40 kb telomeric to the TNFA gene [2] . BAT1 has been shown to downregulate the inflammatory cytokines tumor necrosis factor (TNF)-a and interleukin-6 in in vitro studies [3] . This observation suggests that BAT1 may play an important role in immunopathological disorders.
Chagas disease, caused by infection with the intracellular protozoan parasite Trypanosoma cruzi, affects ∼16-18 million people in Latin America. Chronic Chagas cardiomyopathy (CCC) develops in nearly 30% of individuals 5-30 years after primary infection, and the remaining unaffected individuals are categorized as having the so-called indeterminate or asymptomatic (ASY) form of the disease. CCC can result in a severe form of dilated cardiomyopathy, and patients with CCC who have severe congestive heart failure have a worse clinical course and shorter survival than do patients who have heart failure of other etiologies without the involvement of a prominent inflammatory component [4, 5] .
In patients with CCC, progressive inflammatory events lead to mononuclear-cell infiltration, myocarditis associated with fibrosis, and heart dysfunction [6] . Activated CD8 + T cells are present in the heart tissue of patients with CCC, and TNF-a and interferon (IFN)-g have been found in biopsy samples and surgical heart-tissue samples from patients with CCC [7] . In 2 studies, higher numbers of IFN-g-producing cells among peripheral blood mononuclear cells have been found in patients with CCC than in ASY patients [8, 9] , whereas 1 study has reported the opposite relationship [10] . High plasma Figure 1 . The nt Ϫ22 and Ϫ348 polymorphisms in the promoter region of the BAT1 gene, as detected by NlaIII restriction endonuclease digestion. Lane 1 shows restriction patterns corresponding to homozygosity for the G allele at nt Ϫ22 and for the T allele at nt Ϫ348. Lanes 2 and 3 show heterozygosity at nt Ϫ348 and homozygosity at nt Ϫ22. Lane 4 shows heterozygosity at nt Ϫ22. Lane 5 shows homozygosity at nt Ϫ22 for the C allele and at nt Ϫ348 for the C allele. Lane 6 shows heterozygosity at nt Ϫ22 and at nt Ϫ348. M, molecular-weight marker.
TNF-a levels have also been reported in patients with CCC, compared with those in ASY patients [11] . The increased circulating levels of TNF-a and elevated TNF-a production by heart-infiltrating mononuclear cells suggests that TNF-a is chronically induced in patients with CCC.
The development of CCC in only approximately one-third of individuals infected with T. cruzi and the tendency for its familial aggregation [12] suggest that genetic factors may be involved in such susceptibility. Better control of T. cruzi infection in the host implies that a fine balance has been achieved between the generation of host immune responses that are sufficient to keep the parasitemia in check and the regulation of these responses to avoid tissue damage.
Given the predominant role played by inflammation in CCC, we hypothesized that variants in the BAT1 gene could influence host susceptibility to Chagas disease. Recently, 2 polymorphisms in the promoter region of BAT1, Ϫ22C/G and Ϫ348C/T, have been shown to affect transcriptional activity and the binding of nuclear factors in vitro [13] . Here, we examined these 2 polymorphic sites by conducting an association study that compared patients with CCC and ASY patients.
PATIENTS, MATERIALS, AND METHODS

Patients.
Patients with Chagas disease were recruited at the Heart Institute (InCor) of the Hospital das Clínicas, University of São Paulo. All of the patients were serologically positive for antibodies against T. cruzi and came from 3 major regions of endemicity. The patients were categorized as being ASY (n p ) or as having CCC ( ) on the basis of clinical, ra-76 n p 154 diological, electrocardiographic (ECG), and echocardiographic criteria. All of the ASY patients had normal ECG findings and a normal left ventricular ejection fraction (LVEF) at the time of echocardiography, as well as normal findings for chest, esophagus, and colon radiography. The patients with CCC presented with abnormal ECG findings and were classified as having moderate (LVEF 140%;
) or severe (LVEF р40%; n p 80 ) CCC. The basic characteristics of the studied patients n p 72 are shown in table 1.
BAT1 genotyping. Blood samples from the patients with CCC and the ASY patients were collected after they had provided written, informed consent, in accordance with the guidelines of the Internal Review Board of the Hospital das Clínicas, University of São Paulo. Genomic DNA was extracted by the dodecyltrimethyl ammonium bromide/hexadecyltrimethylammonium bromide method. The polymorphisms at positions Ϫ22 and Ϫ348 in the promoter region of the BAT1 gene were typed by polymerase chain reaction (PCR) restriction fragment-length polymorphism analysis with the restriction enzyme NlaIII (New England Biolabs). The following primer pair flanking both polymorphisms was designed: 5 -CCTCAGGT-CACCTTCACTACC-3 (BAT1 forward) and 5 -CAACAGCG-ACGAAGGAGGGACAT-3 (BAT1 reverse). The BAT1 reverse primer was specifically designed with a TrG substitution to deliberately introduce an NlaIII restriction site when the Ϫ22C allele was present in the genomic DNA; the substitution nucleotide is underscored. PCR was performed in a final volume of 25 mL containing 50 ng of genomic DNA, 1.5 mmol/L MgCl 2 , 0.25 pmol/L forward primer, 0.25 pmol/L reverse primer, 40 mmol/L dNTP, and 2 U of Taq polymerase in buffer containing 100 mmol/L Tris-HCl (pH 8.3) and 500 mmol/L KCl. PCR conditions were an initial denaturation step of 5 min at 95ЊC; 35 cycles of 20 s at 95ЊC, 20 s at 62ЊC, and 30 s at 72ЊC; and a final step of 7 min at 72ЊC. The generated PCR product of 429 bp included a nonpolymorphic NlaIII site that served as an internal control for restriction cleavage, providing fragments of 142 bp and 287 bp. When the Ϫ348T allele was present, the 142-bp fragment was cleaved into 81 and 61 bp, whereas, when the Ϫ22C allele was present, the 287-bp fragment was digested into 267 and 20 bp. PCR restriction fragments were size separated by electrophoresis on 10% polyacrylamide gel ( figure 1) .
Statistical analysis. Statistical analysis was done using GraphPad Prism software (version 4.0; GraphPad Software). Genotype and allele frequencies were calculated by direct counting. Hardy-Weinberg equilibrium (HWE) was assessed for the patients with CCC and the ASY patients by comparing the observed number of different genotypes with those expected under HWE for the estimated allele frequency and by comparing the x 2 distribution with 2 df. Associations between patient groups and a specific allele as well as between patient groups and genotypes were analyzed by the x 2 statistic, along with the relevant odds ratio (OR) and 95% confidence interval (CI). Fisher's exact test was used when a value in the contingency table was !5. The Bonferroni correction was applied for multiple comparisons.
RESULTS
The frequencies of the Ϫ22C/G and Ϫ348C/T polymorphisms of the BAT1 gene were assessed in 154 patients with CCC and 76 ASY patients. The distribution of genotypes in both groups was under HWE. The genotype and allele frequencies of the Ϫ22C/G polymorphism are given in table 2. A significant difference in frequency between the patients with CCC and the ASY patients was revealed at the genotype level for the Ϫ22C/ G polymorphism ( ; )-the proportion of 2 x p 10.0 P p .01 Ϫ22C homozygotes among the patients with CCC was 16%, compared with 4% among the ASY patients ( ; OR, P p .004 4.7 [95% CI, 1.4-16]). When the patients were categorized as those who had the C allele (CC and CG) and those who did not (genotype GG), a statistically significant difference between the patients with CCC and the ASY patients was also found ( ; ). Thus, the Ϫ22C allele seems to confer Both the genotype and the allele distribution of the BAT1 Ϫ348 polymorphism also showed a statistically significant difference between the patients with CCC and the ASY patients, as is shown in table 3. For the CC versus TC plus TT genotype comparison, the OR was 1.9 (95% CI, 1.0-3.5) (
). Strat-P p .01 ification of the patients by LVEF status revealed a borderline statistically significant difference between the patients with CCC who had an LVEF of р40% and the ASY patients for the CC versus TC plus TT comparison ( ; OR, 2.1 [95% CI, P p .04 c 1.1-4.3]). The OR for the comparison between the patients with CCC who had an LVEF of 140% and the ASY patients showed a similar trend but was not significant (OR, 1.8 [95% CI, 0.9-3.6]). The OR for the C versus T allele comparison for Ϫ348C between the patients with CCC and the ASY patients was 1.7 (95% CI, 1.0-2.8) (
). A similar OR trend was P p .02 observed when the patients with CCC were stratified by LVEF status but failed to reach statistical significance after application of the Bonferroni correction.
DISCUSSION
To the best of our knowledge, this is the first study undertaken to examine the potential influence that the BAT1 gene promoter polymorphisms Ϫ22C/G and Ϫ348C/T have on the clinical course of Chagas disease. The major finding is an association between the Ϫ22G/C and Ϫ348C/T polymorphisms of BAT1 and the risk of developing CCC. Patients homozygous for the Ϫ22C variant showed a 5-fold greater risk of developing CCC, compared with patients with either 1 or 0 copies of the risk allele. Similarly, patients homozygous for the Ϫ348C allele showed a 2-fold greater risk of developing CCC.
In a previous study, the BAT1 promoter region (Ϫ22C and Ϫ348C) found in the disease-associated 8.1 ancestral haplotype (AH) (HLA-A1, -B8, and -DR3) consistently showed lower reporter-gene transcriptional activity, compared with the disease-resistant 7.1 AH (HLA-A3, -B7, and -DR15), which carries the Ϫ22G and Ϫ348T variants [14] . Nuclear extracts from T cells, monocytes, and epithelial cells bind to the region spanning the Ϫ22G and Ϫ348T positions, enabling the identification of transcription factors that bind differentially to the 2 alleles [13] . In a transfection reporter assay, the fragment containing the Ϫ22G and Ϫ348T sequences was expressed more efficiently than the fragment containing the Ϫ22C and Ϫ348C sequences [13] . In light of these data, it can be assumed that individual carriage of either the Ϫ22G or the Ϫ348T allele is likely to be associated with an attenuated inflammatory response, compared with that in bearers of the Ϫ22C or Ϫ348C variant. Of note, the Ϫ348T variant is in linkage disequilibrium with the Ϫ22G variant and is found only on chromosomes bearing the Ϫ22G variant. Furthermore, the Ϫ22C and Ϫ348C variants are both found on the 8.1 AH [13] , which has been associated with high TNF-a production [15, 16] .
We previously reported that there was no association between the risk of developing CCC and 2 HLA class II genes (HLA-DR and HLA-DQ) in the Brazilian population [17] . There have been studies that have screened for the TNF-a Ϫ238 and Ϫ308 promoter polymorphisms in patients with Chagas disease. One study reported no association between the risk of developing CCC and these TNF-a promoter polymorphisms in the Peruvian population [18] , whereas another cited an association with the risk of developing CCC in the Mexican population [19] . Progression to chronic Chagas disease is very likely a multifactorial process that depends on the combination of host genetic factors and environmental factors, with each gene contributing slightly to the pathogenesis of the disease. Our present results suggest that BAT1 polymorphisms may be one of these host genetic factors. These polymorphisms either are functionally associated with the development of CCC and, thus, reflect a true association or are in linkage disequilibrium with a critical gene.
Inflammatory-cell infiltrates have been described in autopsied hearts of patients with the ASY form [20] , but recent biopsy studies have shown that patients with CCC who experience heart failure are more likely to have severe myocarditis, fibrosis, and myocardial hypertrophy, suggesting a key role for myocardial inflammation [21] [22] [23] . Hence, progression to overt cardiomyopathy may result from the combined effect of high expression of proinflammatory cytokines [7, 8, 24] triggered by parasite persistence and inadequate counterregulation of these cytokines. Because BAT1 may be a negative regulator of proinflammatory cytokines, we propose that the increased risk for developing CCC among Ϫ22C and Ϫ348C homozygotes reflects an uncontrolled production of inflammatory cytokines that leads to cardiac-tissue damage in these subjects. Indeed, BAT1 appears to be a fast-acting down-regulator of acute-phase cytokines, with a prominent effect on TNF-a [3] .
The overrepresentation of the Ϫ22C variant among the patients with CCC who had an LVEF of 140% can be explained by its coding for low transcriptional activity. On the other hand, the lower prevalence of Ϫ22C homozygotes among the patients with CCC who had an LVEF of р40% (even though it was still higher than that among the ASY patients) might reflect the severity of the disease and selection through the deaths of these patients via this or other intervening susceptibility factors, such as TNF-a production. Indeed, it was recently reported that, in the Brazilian population, Chagas heart disease was associated with the highest risk of death, compared with the risk in patients with heart failure of different etiologies [25] . It can be assumed that we missed these patients with severe disease because of social deprivation [26] , and this might have caused a paucity of patients in that particular cohort subset.
In summary, our results indicate that the Ϫ22C and Ϫ348C promoter polymorphisms in the BAT1 gene are risk factors for the development of CCC in the Brazilian population. This finding sheds new light on the pathogenic mechanism of the disease and raises a potentially interesting issue that is worthy of further study in other populations.
